Avelumab combinations do not improve responses in patients with advanced gynecologic malignancies

December 16, 20231 min
Gynecologist examining patient on chair with gynecological microscope

The immune checkpoint inhibitor avelumab has been approved for multiple cancer types, but has thus far had mixed results in gynecologic patients. A study led by Aung Naing, M.D., was designed to evaluate whether combining avelumab with a 4-1BB agonist (utomilumab), an OX40 agonist (PF-04518600) or radiotherapy would increase efficacy.

Although the combinations proved to be safe, they did not produce significant responses in this heavily pretreated population. In 35 patients evaluated, the overall response rate (ORR) was 2.9% and the disease control rate (DCR) was 37.1%. No dose-limiting toxicities or treatment-related adverse events were observed.

There was a notable result in the cervical cancer population where nine patients who received avelumab plus utomilumab had a DCR of 78%, which could warrant further study for these patients.

MJH footer logo with red letters

Medical Journal – Houston is the leading source of healthcare business news. With extremely relevant content, late-breaking news and monthly exclusives from industry experts, MJH News has created a winning combination of must-read editorial that physicians and hospital executives eagerly anticipate month after month. MJH News is the resource that provides everything they need in one place, and it is a high honor that they rely upon Medical Journal – Houston to keep their practice or hospital on the cutting edge.

Archives